TriMix has been mostly used as a DC-based mRNA vaccine against melanoma because it encodes the activation stimulator CD40L (CD4+ T-cell activator), the costimulatory molecule CD70 (CD8+ T-cell activator), and the constitutively active TLR 4 (DC antigen presentation promotor). Here, CD8A is linked to melanoma.